Metlen Energy & Metals — METKA: A distinct identity via intended IPO

Metlen Energy & Metals (LSE: MTLN; ATHEX: MYTIL)

Last close As at 11/11/2026

EUR45.36

▲ 0.08 (0.18%)

Market capitalisation

EUR6,447m

More on this equity

Research: Industrials

Metlen Energy & Metals — METKA: A distinct identity via intended IPO

Metlen’s dedicated infrastructure platform has announced its intention to proceed with an IPO on Euronext Athens. METKA brings together Metlen’s infrastructure activities (construction, PPP/concessions, facility management) on one integrated platform covering the full lifecycle of infrastructure projects. The proposed offer is expected to consist of new shares in METKA worth c €250m issued via a share capital increase and a secondary offering with the proceeds intended primarily to fund new PPPs and concession investments and provide additional financial flexibility to pursue selected opportunities in adjacent activities. METKA’s intended IPO should be a positive catalyst for Metlen as 2026 continues to shape up well. Our unchanged €75.3/share valuation offers more than 60% upside.

Written by

Jonathan Day

Director of Content, Industrials

Industrials

Intended METKA IPO

12 November 2026

Price €45.28
Market cap €6,437m

Net cash/(debt), FY26e, ex non-recourse

€(1,445.0)m

Shares in issue

142.2m
Free float 78.5%
Code MTLN
Primary exchange LSE
Secondary exchange ATHENS
Price Performance

Business description

Metlen Energy & Metals (previously Mytilineos) is a global industrial and energy company, operating in two main business segments: energy and metallurgy. Metlen is strategically positioned at the forefront of the energy transition as an integrated utility, while also having a successful, fully vertically integrated green metallurgy business. Metlen’s strengths come from its synergies across the entire business, aiding the company’s objective of becoming a global leader.

Analysts

Jonathan Day
+44 (0)20 3077 5700
Harry Kilby
+44 (0)20 3077 5700

Metlen Energy & Metals is a research client of Edison Investment Research Limited

Note: EPS is normalised. DPS is final distributed dividend per share.

Year end EBITDA (€m) Net income (€m) EPS (€) DPS (€) P/E (x) Yield (%)
12/24 1,080.1 620.1 4.50 1.53 10.1 3.4
12/25 752.9 315.1 2.20 1.00 20.6 2.2
12/26e 1,092.5 596.9 4.19 1.47 10.8 3.2
12/27e 1,296.0 743.1 5.22 2.09 8.7 4.6

METKA is an integrated infrastructure platform in Greece with capabilities across construction, public-private partnerships (PPPs) and concessions (through its subsidiary, M Concessions) and facility management (through its subsidiary, UNISON Facility Services, UNISON), spanning the full infrastructure lifecycle. METKA has a growing portfolio of PPPs and concessions and participates across the full lifecycle of infrastructure projects, from origination, design and financing through construction to operation and maintenance. Revenue for the 12 months ended June 2026 was €869m, with EBITDA of €158m, representing a strong 18.2% EBITDA margin. Revenue visibility is supported by the €2.1bn end-June backlog with the balance sheet carrying €166m of adjusted net cash.

The announcement includes a number of key investment highlights: METKA is positioned to capture a multi-year investment cycle in Greece and Southeastern Europe supported by an €83bn cumulative infrastructure gap compared to the European average, anticipated Greek investment in water, road and rail infrastructure plus significant expected investment in Southeastern Europe underpinned by EU and EBRD funding. As one of Greece’s leading infrastructure platforms, the company has an established market position and proven track record in complex infrastructure projects with almost 100% of projects completed on time. The €2.1bn diversified construction backlog equates to c 2.7x last-12 months June 2026 construction revenue providing medium-term visibility. A sound and diversified PPP portfolio and agreed concessions provide long-term cash flow visibility. METKA’s experienced management team has a demonstrable track record of execution and a capital allocation policy designed to balance growth, shareholder returns and financial resilience.

Detailed information about the combined offering will be published in due course, following approval of the prospectus.

We have flagged the potential IPO of METKA as a potential catalyst for Metlen, which recently delivered a strong 9M26 update. The announcement is consistent with our thesis that 2026 is shaping up well, and we make no changes to estimates or our €75.3/share 50/50 DCF/SOTP valuation, implying upside of more than 60%.

General disclaimer and copyright

This report has been commissioned by Metlen Energy & Metals and prepared and issued by Edison, in consideration of a fee payable by Metlen Energy & Metals. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright 2026 Edison Investment Research Limited (Edison).

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London │ New York │ Frankfurt

20 Red Lion Street

London, WC1R 4PS

United Kingdom

More on Metlen Energy & Metals

View All

Latest from the Industrials sector

View All Industrials content

Research: TMT

IP Group — Assessing Pfizer’s anti-obesity royalty potential

IP Group has exposure to Pfizer’s anti-obesity pipeline following the acquisition of Metsera in November 2025 for up to $10bn. Through IP rights underpinning several Metsera-derived programmes, the group is entitled to milestone payments and royalties on future sales, with the associated asset valued at £152m at end-June 2026. Lead candidate berobenatide has delivered encouraging Phase IIb data and is progressing through Phase III, with potential first approval in 2028. Pfizer is funding clinical development, although standard clinical and commercial risks remain. In this note, we assess the programmes’ prospects and use Evaluate Pharma’s consensus sales forecasts to illustrate the scale of IP Group’s potential future royalty income, including outcomes conditional on successful commercialisation.

Continue Reading
Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.